Five years of ocrelizumab in relapsing multiple sclerosis
Stephen L. Hauser(University of California, San Francisco), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Shibeshih Belachew(Roche (Switzerland)), Fabian Model(University Hospital of Basel), Stanislas Hubeaux(University Hospital of Basel), Ludwig Kappos(University Hospital of Basel), Douglas L. Arnold(McGill University), Lahar Mehta(Biogen (United States)), Victoria Levesque(University Hospital of Basel), Harold Koendgen(Roche (Switzerland)), Jerry S. Wolinsky(The University of Texas Health Science Center at Houston), Bruno Brochet(Université de Bordeaux), Amit Bar‐Or(University of Pennsylvania), Marianna Manfrini(University Hospital of Basel), Robert T. Naismith(Washington University in St. Louis), Anthony Traboulsee(University of British Columbia)
Cited by 159
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k